Fig. 2: scRNA-seq reveals that liver group 2 innate lymphoid cells (ILC2) highly express Il13, which may contribute to the blood glucose-lowering effect of IL-33. | Nature Communications

Fig. 2: scRNA-seq reveals that liver group 2 innate lymphoid cells (ILC2) highly express Il13, which may contribute to the blood glucose-lowering effect of IL-33.

From: Liver group 2 innate lymphoid cells regulate blood glucose levels through IL-13 signaling and suppression of gluconeogenesis

Fig. 2: scRNA-seq reveals that liver group 2 innate lymphoid cells (ILC2) highly express Il13, which may contribute to the blood glucose-lowering effect of IL-33.The alternative text for this image may have been generated using AI.

a scRNA-seq data (n = 31,186 single immune cells) for phosphate-buffered saline- and recombinant IL-33 (rIL-33)-treated liver or lung ILC2s, shown as nonlinear representations of the top 50 principal components; the cells are colored based on cell type. b Cell numbers of the clusters within each group, as defined by the treatment condition and tissue. c Differentially expressed genes in each cell type, as defined by the FindAllMarkers function. d Uniform manifold approximation and projection (UMAP) plots of all immune cells showing the expression of Gata3 downstream genes (Il13, IL5, Areg, and Arg1). e Violin plot showing the expression of Il13 and Gata3 in each cluster. f Dot plot showing the expression of Gata3 downstream genes in each cell type.

Back to article page